“`html
ANAHEIM, CA – January 14, 2026
BioCorRx initiates Study of Long-Acting Naltrexone Implant for substance Use
Table of Contents
A new clinical trial is evaluating an implantable naltrexone treatment, perhaps offering a sustained-release option for individuals battling addiction.
- BioCorRx Pharmaceuticals, Inc., a subsidiary of BioCorRx Inc. (OTCID: BICX), has begun a Phase 1 clinical study of BICX104.
- BICX104 is a subcutaneous naltrexone implant designed to release medication for approximately three months.
- The study will compare BICX104, both alone and with bupropion, to the existing extended-release naltrexone injection, Vivitrol®.
- The trial is being conducted under the FDA’s 505(b)(2) regulatory pathway.
BioCorRx Inc. announced today the start of a clinical study evaluating BICX104, an investigational long-acting naltrexone implant, offering a potentially new approach to managing substance use disorders. The study aims to determine the safety and how the body processes BICX104 when administered with or without bupropion, comparing it to the currently approved Vivitrol®.
Understanding the Study Design
the clinical trial, officially titled Safety and Pharmacokinetics Study of BICX104 with or without Bupropion Compared to Vivitrol (ClinicalTrials.gov Identifier: NCT07269873), is underway after receiving necesary institutional review board approvals.researchers will enroll participants into four groups to assess BICX104’s performance, both as a standalone treatment and in combination with bupropion. The implant is designed to maintain consistent naltrexone levels in the body for approximately three months.
BioCorRx also offers solutions for methamphetamine use disorder through a mobile app providing peer support and medication prescribed by a physician.BioCorRx also provides the UnCraveRx® Weight Loss Program, which includes access to nutritionists, fitness experts, and behavioral support specialists.More information on UnCraveRx® can be found at www.uncraverx.com.
Through its subsidiary, biocorrx Pharmaceuticals Inc., the company is also involved in the commercialization and progress of LUCEMYRA® (lofexidine), an FDA-approved medication for managing opioid withdrawal symptoms, and the development of BICX104. Additional details on BioCorRx and its pipeline can be found at www.BioCorRx.com.
Background Information
Research indicates that methamphetamine is a highly addictive stimulant, with over 16.6 million people having used it at least once in their lifetime, according to the 2022 National Survey on drug Use and Health.Opioid use disorder (OUD) is a chronic condition with
